This is a pair of isogenic human astrocyte cell lines, immortalized with hTERT and SV60 and expressing either wildtype (WT) or mutant IDH1 (R132H). The mutant cells produce 2-hydroxyglutarate (2HG), which is an oncometabolite. The cells have been passaged for up to 40 generations. The later generations demonstrate the glioma hypermethylator phenotype. The mutant cells (but not the WT) efficiently form neurospheres in suspension culture and express glioma stem cell markers. This cell set is a system for studying the biology of the IDH1 (R132H) mutation and for screening compounds to target this oncogene.
WT and mutant IDH1 (R132H) were cloned into the pLNCX2 lentiviral vector. These constructs were used to produce lentiviruses, which were then used for infection of the immortalized human astrocyte cell line. Stable cells were selected using the antibiotic G418.
- Timothy A. Chan, MD, PhD, Associate Attending, Department of Radiation Oncology, Memorial Hospital; and Laboratory Head, Human Oncology and Pathogenesis Program, Memorial Hospital Research Laboratories, Memorial Sloan Kettering
- Sevin Turcan, PhD, Research Fellow, Sloan Kettering Institute, Memorial Sloan Kettering
Turcan S et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483 (PubMed ID: 22343889)
Expression of the IDH1 (R132H) mutant is known to remodel the epigenome of cells over time. Both early and late passages of the human astrocyte cell lines expressing WT or mutant IDH1 (R132H) are available.
Cell lines from various passages may be licensed nonexclusively for research or commercial purposes.
- For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, firstname.lastname@example.org
- For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com